NeuroSearch's TIPO-4 study with tesofensine confirms the efficacy in weight management previously reported in TIPO-1 and provides the first long-term data with an average weight loss of 13 to 14 kg

Announcement


NeuroSearch's TIPO-4 study with tesofensine confirms the efficacy in weight
management previously reported in TIPO-1 and provides the first long-term  
data with an average weight loss of 13 to 14 kg                            

NeuroSearch reports positive key results of an interim analysis after the first 
24 weeks of treatment in a 48 weeks clinical Phase II extension study (TIPO-4)  
with the company's drug candidate, tesofensine, for the treatment of obesity and
type II diabetes.                                                               

The TIPO-4 study is designed as an open-label extension to TIPO-1, a 24 week    
clinical Phase II Proof-of-Concept study of tesofensine in obesity, from which  
NeuroSearch reported break-through weight loss results in September 2007 (9 to  
10 kg placebo-corrected weight loss). In TIPO-4, a total of 140 subjects having 
completed treatment in TIPO-1 with either tesofensine (0.25 mg, 0.5 mg or 1.0   
mg) or placebo, have been enrolled after a wash-out period of two months to     
continue treatment with 0.5 mg tesofensine for an additional total of 48 weeks. 

The summary of the interim analysis at 24 weeks of TIPO-4 shows the following   
key results:                                                                    

Patients previously treated with placebo in TIPO-1 achieve in TIPO-4 an average 
weight loss of approximately 9 kg (in addition to the 2 kg they had lost already
during TIPO-1) thus confirming the weight management effect of tesofensine seen 
in TIPO-1 at 0.5 mg under similar treatment conditions and duration.            

Patients previously treated in TIPO-1 with 0.5 mg tesofensine lost almost 4 kg  
in the subsequent treatment on 0.5 mg in TIPO-4. Taking into account the weight 
loss in TIPO-1 inclusive the weight gain during wash-out, the combined effect of
TIPO-1 and TIPO-4 results in an average weight loss of 13 to 14 kg.             

Consistent with earlier clinical results, the 24 weeks safety data from TIPO-4
show that tesofensine is well-tolerated also over extended periods of
administration. The most frequently reported adverse events are unchanged with
dry mouth, insomnia and gastrointestinal disorders. 

Further and more detailed analyses to integrate the efficacy and safety data of 
TIPO- 1 and TIPO-4 are ongoing. In addition, the extension study continues as   
planned with expected reporting from the full 48 weeks extension treatment      
period by end 2008.                                                             

The reported results from the first 24 weeks of TIPO-4 do not change            
NeuroSearch's financial expectations for 2008 of an operating loss in the region
of DKK 450 million.                                                             

Thomas Hofman-Bang  
Chairman of the Board

Contact person: Flemming Pedersen, CEO, telephone: +45 2148 0118
         

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. The core business covers the development of     
novel drugs, based on a broad and well-established drug discovery platform      
focusing on ion channels and CNS disorders. A substantial part of NeuroSearch's 
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III), tesofensine in obesity and in type II diabetes
(Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) 
in partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in      
partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with   
Astellas, ACR325 in Parkinson's disease (Phase II in preparation) and bipolar   
disorder (Phase II in preparation), ABT-107 as well as ABT-560 for the treatment
of various CNS disorders - both (Phase I) in collaboration with Abbott, NSD- 644
in pain (Phase I) in partnership with GSK, ACR343 in Parkinson's disease (Phase 
I) and NSD-788 in anxiety/depression (Phase I). In addition, NeuroSearch has a  
broad portfolio of preclinical drug candidates and holds equity interests in    
several biotech companies.